Japan Ups Generic Use Target
This article was originally published in PharmAsia News
Japan's government has released a new "road map" for the development of the generic drug sector, setting an ambitious new five-year target for such products to reflect faster than expected sales expansion following recent policy changes.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.